Spectra Medical Devices Acquires XL Precision Technologies to Expand CDMO Capabilities

• Spectra Medical Devices has acquired XL Precision Technologies, now a wholly-owned subsidiary.

• The acquisition aims to enhance Spectra’s development and manufacturing capabilities for the medical device industry.

Spectra Medical Devices, a portfolio company of QHP Capital, has announced the acquisition of XL Precision Technologies (XL-PT), a contract development and manufacturing organization (CDMO) that focuses on precision micro-components and complex tubular components for the medical device sector. This acquisition positions XL-PT as a wholly-owned subsidiary of Spectra.

The acquisition enhances Spectra’s capabilities and enables the company to serve a broader range of medical device original equipment manufacturers (OEMs). By combining XL-PT’s precision manufacturing techniques with Spectra’s established reputation in procedural needle manufacturing, the partnership aims to create significant growth opportunities in the years to come.

“We are thrilled to announce Spectra’s acquisition of XL-PT. This acquisition expands and enhances our development and manufacturing capabilities allowing us to do more for our customers and the medical device community,” stated Chad Nikel, CEO of Spectra. The deal is expected to streamline operations and deliver greater value to customers.

Tom Graham, managing director of XL-PT, highlighted the complementary strengths of both companies, saying, “The combination of XL-PT and Spectra brings together highly complementary capabilities: Spectra’s reputation for quality and blue-chip customer base and XL-PT’s exceptional engineering platform and advanced manufacturing techniques.”